[go: up one dir, main page]

WO2008084081A3 - 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders - Google Patents

2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders Download PDF

Info

Publication number
WO2008084081A3
WO2008084081A3 PCT/EP2008/050253 EP2008050253W WO2008084081A3 WO 2008084081 A3 WO2008084081 A3 WO 2008084081A3 EP 2008050253 W EP2008050253 W EP 2008050253W WO 2008084081 A3 WO2008084081 A3 WO 2008084081A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
substituted
phenylpyrimidines
proliferative disorders
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/050253
Other languages
French (fr)
Other versions
WO2008084081A2 (en
Inventor
Barbara Nave
Sven Harmsen
Bernd Mueller
Thomas Grote
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of WO2008084081A2 publication Critical patent/WO2008084081A2/en
Publication of WO2008084081A3 publication Critical patent/WO2008084081A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the use of 2-substituted pyridines of the formulaI and the pharmaceutically acceptable salts of the 2-substituted pyridines of formula I in therapy, in particular in therapy or treatment of cancerous diseases: in which the indices and the substituents are as defined in the claims and the specification.
PCT/EP2008/050253 2007-01-11 2008-01-10 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders Ceased WO2008084081A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100426.1 2007-01-11
EP07100426 2007-01-11

Publications (2)

Publication Number Publication Date
WO2008084081A2 WO2008084081A2 (en) 2008-07-17
WO2008084081A3 true WO2008084081A3 (en) 2008-10-09

Family

ID=39103759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050253 Ceased WO2008084081A2 (en) 2007-01-11 2008-01-10 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders

Country Status (4)

Country Link
AR (1) AR064852A1 (en)
CL (1) CL2008000097A1 (en)
TW (1) TW200836741A (en)
WO (1) WO2008084081A2 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919229A (en) * 1973-07-19 1975-11-11 Labaz Pyrimidine derivatives and process for preparing the same
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
WO2004087678A1 (en) * 2003-04-04 2004-10-14 Basf Aktiengesellschaft 2-substituted pyrimidines
WO2004110453A1 (en) * 2003-06-18 2004-12-23 Pfizer Products Inc. Pyrimidine derivatives as cannabinoid receptor ligands
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
WO2005030216A1 (en) * 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines as anticancer agents
WO2005070899A1 (en) * 2004-01-23 2005-08-04 Bayer Cropscience Ag 5-phenylpyrimidines and their use as microbicides
WO2006079556A2 (en) * 2005-01-31 2006-08-03 Basf Aktiengesellschaft Substituted 5-phenyl pyrimidines i in therapy
WO2008015250A1 (en) * 2006-08-02 2008-02-07 Basf Se Pyrimidine compounds for combating pathogenic fungi and cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919229A (en) * 1973-07-19 1975-11-11 Labaz Pyrimidine derivatives and process for preparing the same
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
WO2004087678A1 (en) * 2003-04-04 2004-10-14 Basf Aktiengesellschaft 2-substituted pyrimidines
WO2004110453A1 (en) * 2003-06-18 2004-12-23 Pfizer Products Inc. Pyrimidine derivatives as cannabinoid receptor ligands
WO2005030216A1 (en) * 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines as anticancer agents
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
WO2005070899A1 (en) * 2004-01-23 2005-08-04 Bayer Cropscience Ag 5-phenylpyrimidines and their use as microbicides
WO2006079556A2 (en) * 2005-01-31 2006-08-03 Basf Aktiengesellschaft Substituted 5-phenyl pyrimidines i in therapy
WO2008015250A1 (en) * 2006-08-02 2008-02-07 Basf Se Pyrimidine compounds for combating pathogenic fungi and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTON ET AL: "Characterization and antimalarial activity of four acetylated pyrimethamines", HETEROCYCLES, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 14, no. 4, 1980, pages 471 - 476, XP009096789, ISSN: 0385-5414 *
CARRAZ G ET AL: "Effects of pyrimethamine amidification by dipropylacetic acid. 1. Decrease of toxicity, persistence of activity on Plasmodium berghei, increase of activity on Toxoplasma Rh (Sabin)", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 9, no. 6, 1974, pages 658 - 659, XP009096848, ISSN: 0223-5234 *
COATS E A ET AL: "CORRELATION ANALYSIS OF PYRIMIDINE FOLIC ACID ANTAGONISTS AS ANTIBACTERIAL AGENTS .L", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 14, no. 3, May 1979 (1979-05-01), pages 261 - 270, XP000985014, ISSN: 0223-5234 *

Also Published As

Publication number Publication date
AR064852A1 (en) 2009-04-29
TW200836741A (en) 2008-09-16
CL2008000097A1 (en) 2008-05-16
WO2008084081A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12018501552A1 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
IN2014DN07384A (en)
PH12013501600A1 (en) Novel heterocyclic derivatives
MX347917B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
IN2012DN02081A (en)
WO2012062925A3 (en) Compounds and methods for treating pain
EA201100971A1 (en) DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
BR112012019765A2 (en) compound, and use of a compound.
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
EA201290603A1 (en) METHOD OF TREATMENT
WO2010121675A3 (en) Thiazolyl-benzimidazoles
TW200833342A (en) 2-substituted pyrimidines I in therapy
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
IN2012DN02816A (en)
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
HK1200456A1 (en) Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701399

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701399

Country of ref document: EP

Kind code of ref document: A2